- Home
- DNLI
as of 01-15-2026 3:54pm EST
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 2.6B | IPO Year: | 2017 |
| Target Price: | $31.58 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.57 - $24.34 | Next Earning Date: | 02-26-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 3973.10% |
AI-Powered DNLI Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Denali Therapeutics Inc. (DNLI)
President and CEO
Avg Cost/Share
$16.50
Shares
35,198
Total Value
$580,767.00
Owned After
296,833
SEC Form 4
COFO and Secretary
Avg Cost/Share
$16.50
Shares
17,218
Total Value
$284,097.00
Owned After
282,828
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Watts Ryan J. | DNLI | President and CEO | Jan 6, 2026 | Sell | $16.50 | 35,198 | $580,767.00 | 296,833 | |
| Schuth Alexander O. | DNLI | COFO and Secretary | Jan 6, 2026 | Sell | $16.50 | 17,218 | $284,097.00 | 282,828 |
Compare DNLI vs Leading Stocks
See how DNLI stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "DNLI Denali Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.